Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis

Cost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis

Journal of Medical Economics ◽

10.3111/200104207219 ◽

2001 ◽

Vol 4 (1-4) ◽

pp. 207-219 ◽

Cited By ~ 9

Author(s):

Uday Bose ◽

David Ladkani ◽

Anita Burrell ◽

Mohammad Sharief

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Cost-Effectiveness of Glatiramer Acetate and Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis, Based on the Combirx Study

Value in Health ◽

10.1016/j.jval.2013.08.1827 ◽

2013 ◽

Vol 16 (7) ◽

pp. A623

Author(s):

J. Darba ◽

L. Kaskens ◽

R.osa R Sánchez-de la

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Relapsing Remitting ◽

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis

Therapeutic Advances in Neurological Disorders ◽

10.1177/1756285611422108 ◽

2011 ◽

Vol 4 (5) ◽

pp. 319-332 ◽

Cited By ~ 26

Author(s):

Aaron Boster ◽

Mary Pat Bartoszek ◽

Colleen O’Connell ◽

David Pitt ◽

Michael Racke

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Relapsing Remitting ◽

Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study

Journal of Medical Economics ◽

10.3111/13696998.2014.890936 ◽

2014 ◽

Vol 17 (3) ◽

pp. 215-222 ◽

Cited By ~ 11

Author(s):

Josep Darbà ◽

Lisette Kaskens ◽

Rainel Sánchez-de la Rosa

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Relapsing Remitting ◽

Cost-Effectiveness Of Delayed-Release Dimethyl Fumarate Compared To Glatiramer Acetate And Fingolimod For The Treatment Of Relapsing-Remitting Multiple Sclerosis

Value in Health ◽

10.1016/j.jval.2014.03.356 ◽

2014 ◽

Vol 17 (3) ◽

pp. A60-A61 ◽

Cited By ~ 2

Author(s):

J.A. Mauskopf ◽

M. Fay ◽

R. Iyer ◽

T. Livingston

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Dimethyl Fumarate ◽

Delayed Release ◽

Relapsing Remitting ◽

PND15: COST-EFFECTIVENESS OF THERAPY FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS): INTRODUCING AN ECONOMIC MODEL FOR COPAXONE (GLATIRAMER ACETATE)

Value in Health ◽

10.1016/s1098-3015(11)71791-0 ◽

2001 ◽

Vol 4 (6) ◽

pp. 523

Author(s):

UK Bose

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Economic Model ◽

Relapsing Remitting ◽

Cost-Effectiveness Analyses of Natalizumab for 2nd Line Versus Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients in Brazil

Value in Health ◽

10.1016/j.jval.2013.08.2248 ◽

2013 ◽

Vol 16 (7) ◽

pp. A721

Author(s):

A.M. Nishikawa ◽

L. Paladini ◽

A.L. Liamas ◽

C.C. Bueno ◽

O.A.C. Clark

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Relapsing Remitting ◽

Multiple Sclerosis Patients ◽

The Cost-Effectiveness Of Delayed-Release Dimethyl Fumarate Versus Glatiramer Acetate For The Treatment Of Relapsing-Remitting Multiple Sclerosis In The Chilean National Health Fund (Fonasa)

Value in Health ◽

10.1016/j.jval.2016.09.491 ◽

2016 ◽

Vol 19 (7) ◽

pp. A431

Author(s):

C Noda ◽

JA de Anda ◽

P Anaya ◽

P Serafini ◽

M Machado

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

National Health ◽

Dimethyl Fumarate ◽

Health Fund ◽

Relapsing Remitting ◽

The Cost ◽

The Cost-Effectiveness Of Delayed Release Dimethyl Fumarate Versus Glatiramer Acetate For The Treatment Of Relapsing-Remitting Multiple Sclerosis In The Mexican Social Security Institute (Imss)

Value in Health ◽

10.1016/j.jval.2016.09.494 ◽

2016 ◽

Vol 19 (7) ◽

pp. A432

Author(s):

JA de Anda ◽

C Noda ◽

P Anaya ◽

A Azamar ◽

M Machado ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Social Security ◽

Glatiramer Acetate ◽

Dimethyl Fumarate ◽

Relapsing Remitting ◽

The Cost ◽

Relapsing Remitting Multiple Sclerosis ◽

Social Security Institute

PND13 A COST-EFFECTIVENESS ANALYSIS OF NATALIZUMAB VS. INTERFERON-BETA AND GLATIRAMER ACETATE IN PATIENTS WITH ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS CURRENTLY FAILING ON EXISTING THERAPY

Value in Health ◽

10.1016/s1098-3015(10)70446-0 ◽

2008 ◽

Vol 11 (3) ◽

pp. A140 ◽

Cited By ~ 1

Author(s):

R Gani ◽

ER Samuels ◽

S Hughes ◽

G Giovanonni

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽